Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017083 | 0.91 | LCK (0.52) | LCKJAK2JAK3MKNK2MKNK1 | |
| SCHEMBL7576852 | 0.87 | LCK (0.71) | LCKJAK2JAK3 | |
| SCHEMBL7019097 | 0.87 | LCK (0.71) | LCKJAK2JAK3 | |
| SCHEMBL7503674 | 0.86 | MKNK2 (0.44) | LCKMKNK2MKNK1 | |
| SCHEMBL7022351 | 0.83 | LCK (0.58) | LCKJAK2JAK3 | |
| SCHEMBL7016544 | 0.79 | LCK (0.61) | LCKJAK2JAK3MKNK2MKNK1 | |
| SCHEMBL7020793 | 0.78 | LCK (0.67) | LCKJAK2JAK3MKNK2MKNK1 | |
| SCHEMBL7571380 | 0.78 | LCK (0.67) | LCKJAK2JAK3MKNK2MKNK1 | |
| SCHEMBL7023575 | 0.78 | LCK (0.71) | LCKJAK2JAK3MKNK2MKNK1 | |
| SCHEMBL7501017 | 0.77 | MKNK2 (0.54) | LCKMKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | claimed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | claimed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |